ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. mcarey@rxir.com To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. The company was founded in 2005 and is based in Lancaster, Pennsylvania. A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . We provide a professional and challenging work environment . The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. Pancreatic cancer is the fourth-most-common cause of cancer-related mortality in the USA. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. 858-366-3243, Internet Explorer presents a security risk. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. CONTACT US. Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Immunomic Therapeutics, Inc. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. 15010 Broschart Road Suite 250. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. For more information, please visit www.immunomix.com. Pay, Holidays and PTO appear to be very good. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. 301-968-3501 Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Description. 28 Employees . You will receive a reply to confirm the receipt of your application. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. ITI Media: Founders Sungwuk Kim. Where the organization is headquartered (e.g. all maps fatal bullet; who is running for senate in maryland 2022 ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. 301-968-3501, ITI Media: People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. Melody Carey Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. immunomic therapeutics crunchbase. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. All content is posted anonymously by employees working at Immunomic Therapeutics. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Join to connect Immunomic Therapeutics, Inc. Mount Saint Mary's College. Contact Email info@immunomet.com. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. ITI Company: / Oct 13, 2015. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. We know that there are multiple aspects that inform our platform's success. ITI-2000 provides an UNITE platform address for HPV+ cancers. All answers shown come directly from Immunomic Therapeutics Reviews and are not edited or altered. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). J Biol Chem. We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. In addition, ITI-1001 represents a far more cost-effective approach. Claim your Free Employer Profile. Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. ITI-ID Candidate Multiple infectious diseases. ITI-1001 GBM - pDNA. Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. In addition, ITI-1001 represents a far more cost-effective approach. ITI Company: The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. For more information, please visit www.immunomix.com. Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. ITI-3000 Merkel Cell Carcinoma - pDNA. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Animal Health All. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. Melody Carey The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. mkemp@immunomix.com ICT has established a broad portfolio of CAR-T products to treat cancer patients. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. Amy Conrad 2017 Jun 12:1-10. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia.